Peculiarities of molecular-biological and hormonal tumor status in patients with endometrial cancer
DOI:
https://doi.org/10.14739/2310-1210.2022.5.257005Keywords:
endometrial cancer, biological tumor markers, expression, estrogens, progesterone, relapseAbstract
Endometrial cancer (EC) ranks second in the structure of oncogynecological diseases both in Ukraine and worldwide. More than 80 % of recurrences occur in the first two years after surgical treatment. Molecular biological markers are extensively studied in different oncological diseases, because they allow to understand the etiology and pathogenesis of malignant growth more deeply.
Aim. To study molecular biological markers and tumor hormonal status in patients with EC and determine their practical significance.
Materials and methods. Molecular biologic markers of the tumor were studied in 89 stage I–IV EC patients. To study the hormonal status of the tumor in EC patients, 119 examinations were carried out.
Results. Significant correlations were found between the level of molecular biological marker (MBM) expression, hormonal status of the tumor, the presence of disease recurrence, and the age of EC patients. The novelty of the study lay in the substantiation of treatment individualization for EC patients based on the determination of the tumor molecular biological characteristics and their prognostic value. It has been proven that the expression level of the studied MBM, ER and PR receptors in EC patients differed depending on age, presence, localization and severity of disease recurrence. A group of patients with a high risk of the disease recurrence has been revealed among EC patients.
For the first time, a technology has been developed for the combined treatment of patients with I–II (T1-2N0M0) stages of EC with a negative receptor status (EP–, PR–) and a high risk of the disease recurrence to assess MBM levels (VEGF, Bcl-2, Ki-67), degree of differentiation, myometrial invasion depth and tumor localization in the uterine cavity allowing to individualize the choice of adjuvant therapy regimen, thus improving the effectiveness of treatment and preventing the occurrence of locoregional relapses and distant metastases.
Conclusions. For the first time, the expression levels of the studied molecular biological markers and ER and PR receptors have been shown to differ depending on age, localization, and relapse severity, which could be used to determine the risk of relapse in EC patients.
References
Fedorenko, Z. P., Hulak, L. O., Mykhailovych, Yu. I., Horokh, Ye. L., Ryzhov, A. Iu., Sumkina, O. V., & Kutsenko, L. B. (2019). Rak v Ukraini, 2017-2018. Zakhvoriuvanist, smertnist, pokaznyky diialnosti onkolohichnoi sluzhby [Cancer in Ukraine, 2017-2018. Morbidity, mortality, performance of the oncology service]. Biuleten Natsionalnoho kantser-reiestru Ukrainy, (20). [in Ukrainian]. http://www.ncru.inf.ua/publications/BULL_20/index.htm
Mikhanovskij, O. A., Sukhina, O. M., Kharchenko, Y. V., Shchyt, N. M., Fedorenko, N. V., Teplova, M. A., & Moiseyenko, Y. A. (2020). Morfolohichne obhruntuvannia radiomodyfikatsii peredoperatsiinoi promenevoi terapii u khvorykh na rozpovsiudzhenyi rak endometriia [Morphological substantiation of radiomodification of preoperative radiotherapy in patients with advanced endometrial cancer]. Ukrainskyi radiolohichnyi ta onkolohichnyi zhurnal, 28(2), 87-105. [in Ukrainian]. https://doi.org/10.46879/ukroj.2.2020.87-105
Aghajanian, C., Filiaci, V., Dizon, D. S., Carlson, J. W., Powell, M. A., Secord, A. A., Tewari, K. S., Bender, D. P., O'Malley, D. M., Stuckey, A., Gao, J., Dao, F., Soslow, R. A., Lankes, H. A., Moore, K., & Levine, D. A. (2018). A phase II study of frontline paclitaxel carboplatin bevacizumab, paclitaxel carboplatin temsirolimus, or ixabepilone carboplatin bevacizumab in advanced recurrent endometrial cancer. Gynecologic Oncology, 150(2), 274-281. https://doi.org/10.1016/j.ygyno.2018.05.018
Wakayama, A., Kudaka, W., Matsumoto, H., Aoyama, H., Ooyama, T., Taira, Y., Arakaki, Y., Shimoji, Y., Nakasone, T., Nishihira, K., Kaneshima, I., Tamaki, T., Yoshimi, N., & Aoki, Y. (2018). Lymphatic vessel involvement is predictive for lymph node metastasis and an important prognostic factor in endometrial cancer. International Journal of Clinical Oncology, 23(3), 532-538. https://doi.org/10.1007/s10147-017-1227-6
Anastasi, E., Gigli, S., Ballesio, L., Angeloni, A., & Manganaro L. (2018). The Complementary Role of Imaging and Tumor Biomarkers in Gynecological Cancers: An Update of the Literature. Asian Pacific Journal of Cancer Prevention, 19(2), 309-317. https://doi.org/10.22034/APJCP.2018.19.2.309
Mikhanovskii, A. A., Kharchenko, Y. V., Teplova, M. A., Krugova, I. N., Moiseyenko, Y. A., Shchyt, N. N., & Pionitkovska, O. V. (2019). Vyznachennia rivnia ekspresii molekuliarno-biolohichnykh markeriv v pukhlyni khvorykh na rak endometriiu I-IV stadii z metoiu prohnozuvannia retsydyvu zakhvoriuvannia [Determination of expression rate of molecular biological markers in tumor of patients with stage I-IV endometrial cancer to predict the disease relapse]. Mizhnarodnyi medychnyi zhurnal, 25(4), 54-58. [in Ukrainian]. https://doi.org/10.37436/2308-5274-2019-4-12
Mikhanovskyi, O. A., Teplova, M. A., Krugova, I. M., Kharchenko, Yu. V., Shchyt, N. M., Fedorenko N. V., & Moiseienko, Yu. A. (2016). Immunogistohimicheskie faktory prognoza raka endometriya [Immunohistochemical factors of endometrial cancer prognosis]. Mezhdunarodnyy meditsinskiy zhurnal, 24(2), 49-52. [in Russian]. http://www.imj.kh.ua/archive/2018/2/10
Chepets, A. V. (2016). Sravnitel'naya immunogistokhimicheskaya kharakteristika ekspressii prognosticheskikh markerov nemetastaticheskoi i metastaticheskoi invazivnoi adenokartsinomy tela matki [Comparison of immunohistochemical characteristics of prognostic markers expression in non-metastatic and metastatic invasive endometrioid endometrial carcinoma]. Zaporozhye Medical Journal, (5), 58-63. [in Russian]. https://doi.org/10.14739/2310-1210.2016.5.82627
Sato, N., Takagi, K., Suzuki, T., Miki, Y., Tanaka, S., Nagase, S., Warita, H., Fukudo, S., Sato, F., Sasano, H., & Ito, K. (2014). Immunolocalization of Corticotropin-releasing hormone (CRH) and its receptors (CRHR1 and CRHR2) in human endometrial carcinoma CRHR1 as a potent prognostic factor. International Journal of Gynecological Cancer, 24(9), 1549-1557. https://doi.org/10.1097/IGC.0000000000000269
Babak,V. P., Biletskyi, A. Ya., Prystavka, O. P., & Prystavka, P. O. (2001). Statystychna obrobka danykh [Statistical data processing]. Kyiv. [in Ukrainian].
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
